Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + pertussis vaccine + hepatitis B vaccine + haemophilus influenzae type b vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Diphtheria toxoid + tetanus toxoid + pertussis vaccine + hepatitis B vaccine + haemophilus influenzae type b vaccine (DTwP-HepB-Hib) is a pentavalent combination vaccine used for the active immunization of infants and young children. It provides protection against five major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and invasive infections caused by Haemophilus influenzae type b. The vaccine typically contains diphtheria and tetanus toxoids, inactivated whole-cell Bordetella pertussis, recombinant hepatitis B surface antigen (HBsAg), and Hib capsular polysaccharide conjugated to a carrier protein (such as tetanus toxoid). Administered via intramuscular injection, it is a cornerstone of pediatric immunization schedules globally, particularly in low- and middle-income countries supported by the WHO Expanded Programme on Immunization (EPI), as it reduces the number of injections required and improves healthcare delivery efficiency.
- Brand names
- QuinvaxemPentavacEasyfiveShan5Shan-5Shan 5ComBE FiveTritanrix-HepB/Hiberix
- Other names
- DTwP-HepB-HibPentavalent vaccineDTP-HepB-Hibdiphtheria, tetanus, pertussis (whole cell), hepatitis B (rDNA) and Haemophilus influenzae type b conjugate vaccine (adsorbed)
02
Targets
HBsAg (Hepatitis B surface antigen)Diphtheria toxin
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + pertussis vaccine + hepatitis B vaccine + haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + pertussis vaccine + hepatitis B vaccine + haemophilus influenzae type b vaccine.